

Daniel Weintraub

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7484166/daniel-weintraub-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

349
papers

26,189
citations

81
h-index

155
g-index

377
ext. papers

31,831
ext. citations

6.4
avg, IF

6.94
L-index

#	Paper	IF	Citations
349	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2017 , 89, 88-100	6.5	1691
348	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012 , 27, 349-56	7	1373
347	Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. <i>Archives of Neurology</i> , 2010 , 67, 589-95		988
346	Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. <i>New England Journal of Medicine</i> , 2006 , 355, 1525-38	59.2	875
345	Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. <i>Neurology</i> , 2009 , 73, 1738-45	6.5	687
344	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S42-80	7	599
343	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. <i>Movement Disorders</i> , 2011 , 26, 1814-24	7	527
342	Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. <i>Neurology</i> , 2010 , 75, 1062-9	6.5	522
341	Association of dopamine agonist use with impulse control disorders in Parkinson disease. <i>Archives of Neurology</i> , 2006 , 63, 969-73		511
340	Depression rating scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2007 , 22, 1077-92	7	490
339	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 217-231	15	458
338	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , 2010 , 9, 573-80	24.1	382
337	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017 , 32, 1264-1310	7	375
336	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Movement Disorders</i> , 2019 , 34, 180-198	7	357
335	Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 682-91	27.4	337
334	Impulse control disorders in Parkinson disease: a multicenter case-control study. <i>Annals of Neurology</i> , 2011 , 69, 986-96	9.4	296
333	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1461-7	7	294

332	Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. <i>Journal of the American Geriatrics Society</i> , 2004 , 52, 784-8	5.6	289
331	Parkinson's disease: the quintessential neuropsychiatric disorder. <i>Movement Disorders</i> , 2011 , 26, 1022-31		277
330	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , 2017 , 16, 55-65	24.1	273
329	CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. <i>Neurology</i> , 2010 , 75, 1055-61	6.5	249
328	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018 , 141, 2181-2193	11.2	245
327	APOE ϵ increases risk for dementia in pure synucleinopathies. <i>JAMA Neurology</i> , 2013 , 70, 223-8	17.2	243
326	Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2008 , 23, 2004-14	7	242
325	Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. <i>Journal of the American Geriatrics Society</i> , 2009 , 57, 304-8	5.6	238
324	The impact of depressive symptoms in early Parkinson disease. <i>Neurology</i> , 2007 , 69, 342-7	6.5	230
323	Clinical spectrum of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1217		203
322	Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. <i>Movement Disorders</i> , 2012 , 27, 242-7	7	202
321	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 66-75	24.1	201
320	Comparison and predictors of rash associated with 15 antiepileptic drugs. <i>Neurology</i> , 2007 , 68, 1701-9	6.5	193
319	Long-term follow-up of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 75-80	7	185
318	Anxiety rating scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2008 , 23, 2015-25	7	182
317	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 919-27	7	179
316	Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. <i>Neurology</i> , 2010 , 75, 448-55	6.5	176
315	Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2006 , 14, 169-75	6.5	166

314	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 81-95	15	165
313	Impulsive and compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1561-70	7	163
312	Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. <i>Journal of Nuclear Medicine</i> , 2005 , 46, 227-32	8.9	156
311	Sertraline for the treatment of depression in Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2010 , 18, 136-45	6.5	154
310	Defining and diagnosing involuntary emotional expression disorder. <i>CNS Spectrums</i> , 2006 , 11, 1-7	1.8	152
309	Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. <i>Neurology</i> , 2013 , 80, 176-80	6.5	150
308	Neurodegeneration across stages of cognitive decline in Parkinson disease. <i>Archives of Neurology</i> , 2011 , 68, 1562-8		149
307	Recognition and treatment of depression in Parkinson's disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003 , 16, 178-83	3.8	149
306	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014 , 29, 857-67	7	148
305	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , 2015 , 85, 1276-82	6.5	144
304	Antidepressant studies in Parkinson's disease: a review and meta-analysis. <i>Movement Disorders</i> , 2005 , 20, 1161-9	7	144
303	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
302	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology</i> , 2015 , 14, 1002-9	24.1	141
301	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016 , 131, 935-49	14.3	138
300	Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 226-31	3.6	138
299	Impulse Control and Related Disorders in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 679-717	4.4	136
298	APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. <i>JAMA Neurology</i> , 2014 , 71, 1405-12	17.2	135
297	[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. <i>Neurology</i> , 2005 , 64, 1716-20	6.5	130

296	Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. <i>American Journal of Managed Care</i> , 2008 , 14, S40-8	2.1	123
295	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. <i>Neurology</i> , 2014 , 82, 2017-25	6.5	122
294	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. <i>Brain</i> , 2012 , 135, 170-80	11.2	122
293	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016 , 73, 1217-1224	17.2	120
292	Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1113-8	5.5	119
291	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 629-34	3.6	118
290	The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. <i>Movement Disorders</i> , 2014 , 29, 1035-43	7	117
289	Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 1660-9	7	117
288	Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. <i>American Journal of Geriatric Psychiatry</i> , 2010 , 18, 332-40	6.5	114
287	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 95-102	7	113
286	Association between cognition and function in patients with Parkinson disease with and without dementia. <i>Movement Disorders</i> , 2010 , 25, 1170-6	7	109
285	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010 , 68, 963-8	9.4	105
284	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. <i>Annals of Neurology</i> , 2011 , 69, 655-63	9.4	103
283	Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2016 , 73, 535-41	17.2	101
282	Genetic influences on cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 512-8	7	100
281	Task force report: scales for screening and evaluating tremor: critique and recommendations. <i>Movement Disorders</i> , 2013 , 28, 1793-800	7	96
280	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 2483-95	7	95
279	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019 , 76, 318-325	17.2	94

278	Suicidal and death ideation in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 1573-9	7	93
277	Dopamine and impulse control disorders in Parkinson's disease. <i>Annals of Neurology</i> , 2008 , 64 Suppl 2, S93-100	9.4	92
276	Psychiatric Complications in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 844-851	5	86
275	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 89	9	85
274	Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. <i>Movement Disorders</i> , 2012 , 27, 858-63	7	85
273	Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. <i>Archives of Neurology</i> , 2011 , 68, 899-904		85
272	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017 , 12, e0175674	3.7	84
271	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018 , 136, 363-376	14.3	83
270	Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. <i>American Journal of Psychiatry</i> , 2007 , 164, 1491-8	11.9	83
269	Course of psychiatric symptoms and global cognition in early Parkinson disease. <i>Neurology</i> , 2014 , 83, 1096-103	6.5	82
268	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018 , 33, 208-218	7	80
267	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016 , 123, 431-8	4.3	76
266	Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 864-70	5.5	76
265	Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. <i>Movement Disorders</i> , 2015 , 30, 912-8	7	76
264	Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. <i>JAMA Neurology</i> , 2015 , 72, 88-95	17.2	73
263	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018 , 33, 771-782	7	73
262	Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. <i>Cognitive and Behavioral Neurology</i> , 2004 , 17, 195-200	1.6	73
261	Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 875-82	4.6	72

260	Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: prevalence, depression, and personality. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 22-6	3.6	70
259	Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1106-11	5.5	70
258	Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2016 , 27, 102-6	3.6	70
257	New evidence on the management of Lewy body dementia. <i>Lancet Neurology, The</i> , 2020 , 19, 157-169	24.1	70
256	Olfactory impairment predicts cognitive decline in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 25, 45-51	3.6	69
255	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019 , 34, 1839-1850	7	69
254	Impulse control and related disorders in Parkinson's disease. <i>Neurodegenerative Diseases</i> , 2013 , 11, 63-71	1.3	68
253	Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 664-72		68
252	Dimensions of executive function in Parkinson's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 20, 140-4	2.6	68
251	Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 3, S110-3	3.6	66
250	Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. <i>Movement Disorders</i> , 2016 , 31, 86-94	7	66
249	CSF β Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. <i>Journal of Molecular Neuroscience</i> , 2016 , 58, 88-92	3.3	63
248	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 688-95	7	63
247	Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016 , 31, 625-31	7	63
246	Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1809-15	7	62
245	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1581-7	2.9	61
244	Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2016 , 173, 465-72	11.9	60
243	Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. <i>Neurology</i> , 2014 , 83, 826-33	6.5	59

242	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016 , 23, 1255-61	6	58
241	Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts. <i>Neurology: Genetics</i> , 2019 , 5, e348	3.8	57
240	Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 2051-7	7	57
239	Effect of age on geriatric depression scale performance in Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1331-5	7	56
238	Impulse control disorders in Parkinson's disease. <i>Current Neurology and Neuroscience Reports</i> , 2006 , 6, 302-6	6.6	56
237	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 47	51.1	55
236	High patient satisfaction with telehealth in Parkinson disease: A randomized controlled study. <i>Neurology: Clinical Practice</i> , 2016 , 6, 241-251	1.7	55
235	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 787-795	4.3	54
234	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019 , 142, 3592-3604	11.2	54
233	Cognitive impairment and PD patients' capacity to consent to research. <i>Neurology</i> , 2013 , 81, 801-7	6.5	53
232	Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 153-5	3.6	52
231	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 325-331	5.5	51
230	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 287-95	4.3	50
229	Advances in the treatment of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1471-89	7	50
228	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. <i>Movement Disorders</i> , 2014 , 29, 1258-64	7	50
227	Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 55-64	1.2	50
226	Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 78-88	5.5	49
225	Longitudinal analyses of cerebrospinal fluid β -Synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1354-1364	7	48

224	Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. <i>American Journal of Psychiatry</i> , 2016 , 173, 473-80	11.9	48
223	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinsons Disease</i> , 2016 , 2,	9.7	45
222	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 998-1018	6.5	44
221	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 270-9	7	44
220	CSF tau and α -Synuclein predict cerebral synucleinopathy in autopsied Lewy body disorders. <i>Neurology</i> , 2018 , 90, e1038-e1046	6.5	43
219	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016 , 31, 1619-1622	7	43
218	Cognitive profile of LRRK2-related Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 728-33	7	42
217	Citalopram for agitation in Alzheimer's disease: design and methods. <i>Alzheimer's and Dementia</i> , 2012 , 8, 121-30	1.2	42
216	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , 2016 , 23, 1556-65	6	42
215	Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study # 2 (DIADS-2)? <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 573-83	3.9	41
214	R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 784-92	3.8	41
213	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019 , 85, 259-271	9.4	41
212	Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. <i>PLoS ONE</i> , 2014 , 9, e98426	3.7	40
211	Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. <i>Journal of Neurology</i> , 2018 , 265, 1365-1375	5.5	39
210	Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2008 , 21, 123-32	3.8	39
209	Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017 , 43, 604-620	5.2	38
208	Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007 , 20, 161-5	3.8	38
207	Psychiatric issues in cognitive impairment. <i>Movement Disorders</i> , 2014 , 29, 651-62	7	37

206	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology, The</i> , 2020 , 19, 71-80	24.1	37
205	Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. <i>Movement Disorders</i> , 2016 , 31, 709-14	7	36
204	Psychiatric complications in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 844-51	6.5	36
203	The course of depressive symptoms in early Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1306-11	7	34
202	Psychiatric assessment of a nursing home population using audiovisual telecommunication. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001 , 14, 63-5	3.8	34
201	Initial cognitive changes in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 511-519	7	33
200	Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2016 , 74, 17-21	5.2	33
199	Cognitive outcomes after sertraline treatment in patients with depression of Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2012 , 20, 1036-44	6.5	33
198	The movement disorder society nonmotor rating scale: Initial validation study. <i>Movement Disorders</i> , 2020 , 35, 116-133	7	33
197	Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. <i>Npj Parkinsons Disease</i> , 2018 , 4, 2	9.7	32
196	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. <i>Journal of Neurology</i> , 2014 , 261, 936-42	5.5	32
195	Impulse control and related disorders in Mexican Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 907-10	3.6	32
194	Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. <i>Neurology</i> , 2010 , 75, 478; author reply 478-9	6.5	32
193	Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2011 , 26, 443-9	2.5	32
192	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020 , 35, 1999-2008	7	32
191	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinsons Disease</i> , 2017 , 7, 533-543	5.3	31
190	Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2015 , 5, 783-92	5.3	31
189	Medication management and neuropsychological performance in Parkinson's disease. <i>Clinical Neuropsychologist</i> , 2012 , 26, 45-58	4.4	30

188	Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006 , 12, 427-31	3.6	30
187	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 1640-1645	7	29
186	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. <i>Movement Disorders</i> , 2015 , 30, 805-12	7	29
185	Is depression in Parkinson's disease (PD) a specific entity?. <i>Journal of Affective Disorders</i> , 2012 , 139, 103-106	6.2	29
184	Cerebrospinal fluid β -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1052-1062	1.2	27
183	Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 1410-7	6.5	27
182	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 25, 21-6	3.6	27
181	Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?. <i>Movement Disorders</i> , 2013 , 28, 1915-9	7	26
180	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 15-25	5.3	26
179	Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 346-55	5.3	26
178	Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. <i>European Journal of Neurology</i> , 2019 , 26, 246-e18	6	26
177	Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. <i>JAMA Neurology</i> , 2019 , 76, 41-49	17.2	26
176	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. <i>Brain and Language</i> , 2017 , 171, 42-51	2.9	25
175	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019 , 34, 791-798	7	25
174	Regional brain amyloid- β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. <i>PLoS ONE</i> , 2017 , 12, e0177924	3.7	25
173	Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking. <i>Movement Disorders</i> , 2015 , 30, 859-62	7	25
172	Antipsychotic Use and Physical Morbidity in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017 , 25, 697-705	6.5	24
171	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017 , 56, 211.e1-211.e7	5.6	24

170	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinsons Disease</i> , 2019 , 5, 7	9.7	24
169	Caregiver report of apathy predicts dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 992-5	3.6	24
168	Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006 , 18, 377-83	2.7	24
167	APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 289-297	7	24
166	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. <i>Annals of Neurology</i> , 2019 , 85, 801-811	9.4	23
165	Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators. <i>Parkinsonism and Related Disorders</i> , 2005 , 11, 403-6	3.6	23
164	Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 367-375	2.2	22
163	Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. <i>Alzheimer's and Dementia</i> , 2013 , 9, 609-14	1.2	22
162	Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilization. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 543-8	3.9	22
161	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018 , 33, 1750-1759	7	22
160	The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017 , 39, 31-36	3.6	21
159	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018 , 13, e0201964	3.7	21
158	Electroconvulsive Therapy for Epilepsy and Major Depression. <i>American Journal of Geriatric Psychiatry</i> , 1998 , 6, 180-183	6.5	21
157	Amphetamine positive toxicology screen secondary to bupropion. <i>Depression and Anxiety</i> , 2000 , 12, 53-48.4		21
156	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , 2019 , 34, 430-435		21
155	Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 1127-33	6.5	20
154	Benefit finding and relationship quality in Parkinson's disease: a pilot dyadic analysis of husbands and wives. <i>Journal of Family Psychology</i> , 2014 , 28, 728-34	2.7	20
153	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. <i>Npj Parkinsons Disease</i> , 2019 , 5, 30	9.7	20

152	Pattern of Depressive Symptoms in Parkinson's Disease. <i>Psychosomatics</i> , 2009 , 50, 448-454	2.6	19
151	Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2009 , 17, 986-95	6.5	19
150	Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy. <i>Seminars in Neurology</i> , 2017 , 37, 186-192	3.2	18
149	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020 , 35, 833-844	7	18
148	Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2017 , 43, 49-55	3.6	18
147	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. <i>PLoS ONE</i> , 2016 , 11, e0147319	3.7	18
146	Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021 , 385, 309-319	5.2	18
145	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 449-461	5.3	18
144	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018 , 33, 1769-1776	7	18
143	Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS). <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 227-234	2.2	17
142	Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis. <i>PLoS Medicine</i> , 2019 , 16, e1002931	11.6	17
141	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. <i>International Psychogeriatrics</i> , 2015 , 27, 2059-67	3.4	17
140	Frequency and correlates of involuntary emotional expression disorder in Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009 , 21, 406-12	2.7	17
139	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020 , 88, 574-587	9.4	16
138	Involuntary emotional expression disorder (IEED) in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 511-5	3.6	16
137	Nortriptyline toxicity secondary to interaction with bupropion sustained-release. <i>Depression and Anxiety</i> , 2001 , 13, 50-2	8.4	16
136	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. <i>Movement Disorders</i> , 2016 , 31, 126-34	7	16
135	Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , 2021 , 36, 106-117	7	16

134	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021 , 143, 3-12	3.8	16
133	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. <i>Journal of Parkinsons Disease</i> , 2017 , 7, 385-395	5.3	15
132	Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018 , 33, 450-457	2.5	15
131	Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15). <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 1025-30	3.9	15
130	Phenylthiocarbamide (PTC) perception in Parkinson disease. <i>Cognitive and Behavioral Neurology</i> , 2007 , 20, 145-8	1.6	15
129	Impulse Control Disorders in Parkinson's Disease. <i>American Journal of Psychiatry</i> , 2019 , 176, 5-11	11.9	15
128	Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. <i>Journal of Parkinsons Disease</i> , 2014 , 4, 585-9	5.3	14
127	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 127-134	2.2	14
126	Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. <i>European Journal of Neurology</i> , 2013 , 20, 1198-203	6	14
125	Case for and against specificity of depression in Alzheimer's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2010 , 64, 358-66	6.2	14
124	Daily affect in Parkinson disease is responsive to life events and motor symptoms. <i>American Journal of Geriatric Psychiatry</i> , 2006 , 14, 161-8	6.5	14
123	Cognition in movement disorders: where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014 , 29, 704-11	7	13
122	The Case for Antipsychotics in Dementia with Lewy Bodies. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 32-35	2.2	12
121	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. <i>Movement Disorders</i> , 2020 , 35, 1618-1625	7	12
120	Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders</i> , 2018 , 33, 839-843	7	11
119	Delirious mania in the elderly. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 374-7	3.9	11
118	Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. <i>Neurology</i> , 2021 , 96, e1855-e1864	6.5	11
117	Pharmacological treatment of apathy in Lewy body disorders: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 14-24	3.6	11

116	Impulse control and related behaviors in Parkinson's disease with dementia. <i>European Journal of Neurology</i> , 2020 , 27, 944-950	6	10
115	From action to abstraction: The sensorimotor grounding of metaphor in Parkinson's disease. <i>Cortex</i> , 2019 , 121, 362-384	3.8	10
114	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2017 , 7, 661-667	5.3	10
113	Sertraline for the treatment of depression in Alzheimer disease: genetic influences. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011 , 24, 222-8	3.8	10
112	Treatment of early Parkinson's disease. Part 1. <i>European Neurology</i> , 2009 , 61, 193-205	2.1	10
111	Treatment of early Parkinson's disease. Part 2. <i>European Neurology</i> , 2009 , 61, 206-15	2.1	10
110	Effect of increasing the dose and duration of sertraline trial in the treatment of depressed nursing home residents. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003 , 16, 109-11	3.8	10
109	The neuropsychiatry of Parkinson's disease: advances and challenges.. <i>Lancet Neurology, The</i> , 2022 , 21, 89-102	24.1	10
108	Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder. <i>Brain Imaging and Behavior</i> , 2019 , 13, 1352-1360	4.1	10
107	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1760-1768	7	10
106	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 201-209	3.6	9
105	Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 712-719	6.5	9
104	Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics. <i>Neurotherapeutics</i> , 2020 , 17, 1511-1524	6.4	9
103	Research consent capacity varies with executive function and memory in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 414-7	7	9
102	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 440-445	2.2	9
101	Pharmacologic management of psychosis in the elderly: a critical review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003 , 16, 213-8	3.8	9
100	Residents in Personal Psychotherapy. <i>Academic Psychiatry</i> , 1999 , 23, 14-19	1.1	9
99	Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 161-167	2.2	9

98	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 2583-2594	7	9
97	Impulse control disorders in Parkinson's disease: A 20-year odyssey. <i>Movement Disorders</i> , 2019 , 34, 447-452		8
96	Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. <i>Neurology</i> , 2015 , 84, 1386-7	6.5	8
95	Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases: evidence about efficacy and safety. <i>Psychiatric Clinics of North America</i> , 2005 , 28, 941-83, ix-x	3.1	8
94	Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 32-36	2.2	8
93	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2342-2355	5.3	8
92	Hospital care for mental health and substance abuse conditions in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1810-1819	7	8
91	Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the MDS-NMS. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 231-239	2.2	8
90	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 1209-1219	5.3	8
89	Is the Parkinson Anxiety Scale comparable across raters?. <i>Movement Disorders</i> , 2015 , 30, 545-51	7	7
88	A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016 , 43, 99-109	2.7	7
87	Second-generation issues in the management of depression in nursing homes. <i>Journal of the American Geriatrics Society</i> , 2002 , 50, 2100-1; author reply 2101	5.6	7
86	Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2020 , 46, 707-721	5.2	7
85	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 395-404	5.3	7
84	Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2019 , 69, 119-124	3.6	7
83	Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016 , 29, 59-64	3.8	6
82	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). <i>Parkinsonism and Related Disorders</i> , 2019 , 63, 117-123	3.6	6
81	Is Rapid Eye Movement Sleep Behavior Disorder a Risk Factor for Impulse Control Disorder in Parkinson Disease?. <i>Annals of Neurology</i> , 2020 , 88, 759-770	9.4	6

80	Pattern of depressive symptoms in Parkinson's disease. <i>Psychosomatics</i> , 2009 , 50, 448-54	2.6	6
79	Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients: A Case-Control Study. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	6
78	Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment. <i>Movement Disorders</i> , 2021 , 36, 2549-2558	7	6
77	Dopamine transporter imaging predicts clinically-defined α -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 201-212	5.3	6
76	The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 3004-3005	11.5	5
75	Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019 , 402, 81-85	3.2	5
74	Factor Analysis and Clustering of the Movement Disorder Society-Non-Motor Rating Scale. <i>Movement Disorders</i> , 2020 , 35, 969-975	7	5
73	Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 14-24	6.5	5
72	Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. <i>International Journal of Neuroscience</i> , 2011 , 121, 472-6	2	5
71	Intervening in the neuropsychiatric features of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2007 , 7, 699-710	4.3	5
70	Nortriptyline in geriatric depression resistant to serotonin reuptake inhibitors: case series. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001 , 14, 28-32	3.8	5
69	Change in the rate of restraint use and falls on a psychogeriatric inpatient unit: impact of the health care financing administration's new restraint and seclusion standards for hospitals. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002 , 15, 91-4	3.8	5
68	Direct Medical Costs of Dementia With Lewy Bodies by Disease Complexity. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 1696-1704.e5	5.9	5
67	Measurement properties from the Brazilian Portuguese version of the QUIP-RS. <i>Npj Parkinsons Disease</i> , 2020 , 6, 6	9.7	4
66	Introduction: the importance of cognition in movement disorders. <i>Movement Disorders</i> , 2014 , 29, 581-3	7	4
65	Multimodal in vivo and postmortem assessments of tau in Lewy body disorders. <i>Neurobiology of Aging</i> , 2020 , 96, 137-147	5.6	4
64	Frequency of and risk factors for potentially inappropriate medication use in Parkinson's disease. <i>Age and Ageing</i> , 2020 , 49, 786-792	3	3
63	Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire [Current Short (QUIP-CS)] Translation and validation of content of Portuguese Version. <i>Jornal Brasileiro De Psiquiatria</i> , 2017 , 66, 111-115	0.5	3

62	Both the body and brain benefit from exercise: potential win-win for Parkinson's disease patients. <i>Movement Disorders</i> , 2011 , 26, 607	7	3
61	Psychiatric Issues in Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010 , 34, 213-228		3
60	Disorders of mood and affect in Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 83, 421-33	3	3
59	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2020 , 140, 449-461	14.3	3
58	Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021 , 8919887211023586	3.8	3
57	Principal components analysis of agitation outcomes in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2016 , 79, 4-7	5.2	3
56	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. <i>Movement Disorders</i> , 2021 ,	7	3
55	Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1313-1318	5.5	3
54	Cognitive decline before diagnosis of Parkinson's disease - Authors' reply. <i>Lancet Neurology</i> , 2017 , 16, 262	24.1	2
53	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. <i>Frontiers in Neuroscience</i> , 2017 , 11, 53	5.1	2
52	Treatment changes among older patients with dementia treated with antipsychotics. <i>International Journal of Geriatric Psychiatry</i> , 2015 , 30, 1238-49	3.9	2
51	Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. <i>Neurology</i> , 2013 , 81, 694-5	6.5	2
50	Impulse control disorders and related behaviors	140-152	2
49	Therapeutic options for emotional lability: current and emerging treatments. <i>American Journal of Geriatric Pharmacotherapy</i> , 2005 , 3 Suppl A, 12-5; quiz 16-7		2
48	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. <i>Neurology: Clinical Practice</i> , 2021 , 11, 105-116	1.7	2
47	Diagnosing and Treating Depression in Patients With Parkinson's Disease. <i>Psychiatric Annals</i> , 2004 , 34, 298-304	0.5	2
46	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression		2
45	Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?. <i>BMC Neurology</i> , 2021 , 21, 240	3.1	2

44	Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx). <i>Journal of Parkinsons Disease</i> , 2016 , 6, 383-92	5.3	2
43	The Danger of Not Treating Parkinson Disease Psychosis-Reply. <i>JAMA Neurology</i> , 2016 , 73, 1156-7	17.2	2
42	Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. <i>Scientific Reports</i> , 2021 , 11, 23645	4.9	2
41	Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. <i>Frontiers in Human Neuroscience</i> , 2016 , 10, 693	3.3	1
40	Anxiety Syndromes and Panic Attacks 2011 , 193-201		1
39	A Model to Assess the Outcomes Associated With Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2021 , 35, 68-74	2.5	1
38	An International Multicenter Analysis of Brain Structure across Clinical Stages of Parkinson Disease: The ENIGMA-Parkinson Study		1
37	Hallucinations and Development of Dementia in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2020 , 10, 1643-1648	5.3	1
36	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021 , 11, e02086	3.4	1
35	Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 757-765	5.3	1
34	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 737-745	5.3	1
33	Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 1972-1978	7	1
32	Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1181-1188	2.2	1
31	Validation of the Japanese Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS).. <i>Parkinsons Disease</i> , 2022 , 2022, 1503167	2.6	1
30	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018 , 33, 499-500	7	0
29	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 501-502	7	0
28	Movement in Aesthetic Experiences: What We Can Learn from Parkinson Disease. <i>Journal of Cognitive Neuroscience</i> , 2021 , 33, 1329-1342	3.1	0
27	Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 35-47	6.5	0

- 26 Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia..
Movement Disorders Clinical Practice, **2022**, 9, 479-483 2.2 0
- 25 Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease 325-336
- 24 Does a Positive Amyloid Scan Always Mean Alzheimer Disease? **2020**, 99-102
- 23 I Don't Know When to Stop **2020**, 149-152
- 22 Caring for the Caregiver **2020**, 155-157
- 21 Cognitive Decline Is Only Part of the Story **2020**, 4-6
- 20 Not Recognizing the Impostor **2020**, 64-66
- 19 Cognitive Impairment as an Unexpected Guest **2020**, 75-77
- 18 What Is Not How I Feel **2020**, 96-98
- 17 Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al. *Movement Disorders*, **2015**, 30, 1711 7
- 16 The boundaries of Parkinson's disease dementia and dementia with Lewy bodies 40-52
- 15 Cognitive assessment in Parkinson's disease 53-64
- 14 Clinical assessment: mood and motivation 65-72
- 13 Diagnosis and biomarkers: CSF 97-108
- 12 Apathy 131-139
- 11 Psychosis 153-162
- 10 Early cognitive impairment 163-176
- 9 Parkinson's disease dementia 177-191

8 Sleep disturbances 192-210

7 The impact of neuropsychiatric symptoms on quality of life in Parkinson's disease 255-260

6 Neuropsychiatric aspects of the on/off phenomenon 275-284

5 Drs. Weintraub and Hurtig Reply. *American Journal of Psychiatry*, **2008**, 165, 261 11.9

4 0075 Neural Correlates of Cognitive Fatigue in Parkinson Disease. *Sleep*, **2020**, 43, A30-A30 1.1

3 Clinical Follow-up of Parkinson's Disease With Newly Prescribed Quetiapine. *Movement Disorders*, **2020**, 35, 1690-1692 7

2 Assessment of Affective-Behavioral States in Parkinson's Disease Patients: Towards a New Screening Tool. *Journal of Parkinsons Disease*, **2021**, 11, 1417-1430 5.3

1 Clinical and demographic changes over ten years on a psychogeriatric inpatient unit. *Annals of Clinical Psychiatry*, **2000**, 12, 227-31 1.4